Resmed

From Bluescope to Resmed to WiseTech and Cettire, an unfolding global trade war will have far reaching implications for some of the biggest names on the ASX.

Miracle drugs, battery tech and a private equity reckoning. This is what fund managers are thinking about in the new year.

Investors are split over an emerging group of fat loss treatments and their market implications.